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1. INTRODUCTION 
The disease called coronavirus disease 2019 (COVID-19) has become an epidemic in 
Wuhan City, Hubei Province, China, in December 2019. COVID-19 is caused by severe acute 
respiratory Coronavirus two syndromes (SARS-CoV-2), previously known as 2019-nCoV.1 
COVID-19 is an acute respiratory infection caused by a new type of 
Coronavirus, SARS-CoV-2, which first appeared in Wuhan, China in 
December 2019. COVID-19 then became a pandemic in various 
countries in early 2020. In this article it contains review that discusses 
the immune response in humans due to SARS-CoV-2 infection, using 
the narrative literature review method, a total of 36 articles (6 from 
Elsevier, 24 from PMC, and six from Springer). It is known that the 
pathogenesis of COVID-19 and the manufacture of drugs and vaccines 
are still under investigation, but in infected patients, innate immune 
responses in the form of alveolar macrophages, dendritic cells, airway 
epithelial cells, congenital lymphocytes, and neutrophils work together 
in the fight against infection. Next comes the adaptive immune response 
in the form of antibodies (immunoglobulins) which help in fighting 
infections due to SARS-CoV-2. These immune responses include 
increasing levels of cytokines, coagulation parameters, C-reactive 
protein, neutrophils, and decreasing total lymphocytes. It is also known 
that COVID-19 patients with severe disease often experience higher 
total antibody, IgM responses, and IgG responses than COVID-19 
patients without the congenital disease. IgG antibodies are present in 
the serum, so the serum in COVID-19 patients who have recovered can 
be used for therapy in COVID-19 patients who have not healed, as long 
as the drug and vaccine are under investigation. 
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SARS-CoV-2 became a pandemic in various countries until early 2020.2 The virus was named 
SARS-CoV-2 because it has genetic similarities with SARS-CoV of the genus Betacoronavirus 
which was an epidemic in 2002-2003.3,4  
On April 30, 2020, WHO stated globally 3,090,445 positive cases were confirmed to 
be COVID-19 with 217,769 deaths.5 While in Indonesia, as of May 08, 2020, there were 13,112 
confirmed positive cases of COVID-19, with 2,494 victims recovered, and 943 victims died.6 
In Indonesia, it's also known that COVID-19 fatality rate is quite high in five provinces, namely 
Banten (11.1%), East Java (10.7%), DKI Jakarta (8.6%), Central Java (7% ), and West Java 
(6.6%). In addition to these provinces, there are five provinces that report the highest cure 
rates, namely Riau Islands, Bali, Aceh, Gorontalo, and DI Yogyakarta.7  
SARS-CoV-2 infects humans thought to have originated from bats sold in the largest 
seafood market in Wuhan.1 Infected humans can transmit the SARS-CoV-2 virus through 
sparks from the nose or mouth when coughing, sneezing, and or when breathing.8 These 
splashes can fall on nearby objects or surfaces, and people who touch the object or surface 
and then touch their eyes, nose or mouth can also be infected with SARS-CoV-2 because the 
virus from the hands moves and enters the lungs.8,9  
SARS-CoV-2 infection can cause mild, moderate or severe symptoms.10 The main 
clinical symptoms are fever ˃38 ° C, dry cough, and difficulty breathing.11 In some cases, even 
to experience heavy congestion, severe fatigue, muscle aches, and diarrhoea.12 Some 
patients experience shortness of breath for one week with severe cases such as acute 
respiratory distress syndrome (ARDS), shock, septic, metabolic acidosis, and bleeding.10,12  
SARS-CoV-2 is an RNA virus that has a spike glycoprotein (protein S) that can bind to 
the angiotensin-converting enzyme 2 (ACE2) receptor.13 The S protein enters the host cell by 
attaching and binding to the ACE2 receptor, so the receptor-binding domain (RBD) of the S 
protein automatically recognizes that the receptor belongs to the host.14 This can eventually 
combine the virus with the host membrane, and then the virus antigen will be exposed to the 
antigen presentation cell (APC).15 ACE2 in the lungs is found in type 2 alveolar cells,16 this is 
what causes in the case of COVID 19 symptoms such as peneumonia.7  
The pathogenesis of COVID-19 and the manufacture of drugs and vaccines are still 
under investigation. For most patients, COVID-19 can only affect the lungs because most are 
respiratory diseases, with the main mode of infection being human-to-human transmission 
through direct contact from infected individuals through coughing or sneezing. COVID-19 has 
a possible asymptomatic incubation period of 2-14 days during which the virus can be 
transmitted.12 When the virus infects, the antigen will be recognized by the immune system, 
so that an immune response is formed. To find out the immune response formed, the 
researchers conducted a review of various journals related to SARS-CoV-2 and the immune 
response in the human body. 
 
2. REVIEW METHOD 
The review method used in this article is a narrative review, which is a way to review 
existing literature and lean to the qualitative interpretation of prior knowledge, by summarizing 
or synthesizing what has been written on a particular topic but not looking for generalizations 
or cumulative knowledge from what is reviewed.17 Articles were searched for keywords 
COVID-19 and SARS-CoV-2. 19.940 articles were obtained (849 from Elsevier, 9,547 from 
PMC, and 830 from Springer). The inclusion criteria we used were articles that discussed 
human immune responses to SARS-CoV-2 infection (based on previous SARS-CoV 
infections), which were fully accessible. From these criteria, 36 articles were obtained (6 from 
Elsevier, 24 from PMC, and 6 from Springer). The articles used are articles published in 2002-
2020. This article discusses how SARS-CoV-2 infects host cells, and the human immune 
response infected with SARS-CoV-2. The data obtained is then described and supported by 
relevant references obtained from credible sources.  
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3. RESULTS AND DISCUSSION 
 
How to SARS-COV-2 infect a human (Based on SARS-COV) 
SARS-CoV-2 is a new Coronavirus subfamily that belongs to the β-coronavirus family 
which has 79.5% genetic similarity with SARS-CoV, the causative agent of the epidemic in 
2002-2003.18 SARS-CoV-2 has a genome structure like Coronavirus in general, which 
includes RNA viruses with particle sizes of 120-160 nm.15 SARS-CoV-2 is thought to originate 
from bats which then mutate and infect humans. SARS-CoV-2 is closely related to 
Coronavirus in bats (Bat-SL-CoV ZC45 2018) and also Coronavirus in pangolins (Pangolin-
CoV GX-P5E 2017).7 There are no significant differences in the SARS-CoV-2 glycoprotein 
spike gene sequence found in Indonesia and the Wuhan-Hu-1 isolate from China.19 SARS-
CoV-2 has 96.2% genetic similarity with bat Coronavirus,1 and have a 91% genome similarity 
to the anteater Coronavirus.15 The structure of SASR-CoV-2 also has similarities with other 
SARS viruses.20 The body structure of SARS-CoV-2 is presented in figure 1. 
 
 
Figure 1. SARS-CoV-2 Body Structure3 
 
The structure of SARS-CoV-2 consists of spike glycoprotein (protein S), protein 
envelope (E), membrane protein (M), hemagglutinin-esterase (HE), nucleocapsid (N), and 
genomic RNA. S protein is the only viral protein responsible for the entry of the virus into the 
host cell,21 S protein protrudes from the virion envelope and plays an important role in 
attaching the body of the virus to the host receptor.22,23 Protein E is the smallest protein that 
is abundantly expressed in infected cells, where it participates in the assembly and 
development of CoV.24 M protein is the most abundant protein and forms E protein, M protein 
is directly related to nucleocapsid and together encourages the formation of protein E in 
viruses.24 Hemagglutinin-esterase (HE) is a part of protein E which acts as a lectin and is a 
receptor-destroying enzyme.25 The nucleocapsid (N) is seen as a ribonucleoparticle (RNP) 
because its components correspond to the RNA genome, which is coated by a nucleocapsid 
protein molecule. Nucleocapsid proteins interact with the RNA genome and coat the genome 
extensively.26 RNA genome is the genetic material in the form of a ribonucleic acid single 
strand (ssRNA) or double-strand (dsRNA) that functions as a store of genetic information and 
can replicate.27 In SARS-CoV-2 RNA that is owned is single-stranded RNA (ssRNA).28  
SARS-CoV-2 has similarities with SARS-CoV which requires specific cellular receptors 
to infect host cells, namely, angiotensin-converting enzyme 2 (ACE2).29 ACE2 is a receptor in 
the form of a central enzyme in the renin-angiotensin system, which negatively regulates the 
renin-angiotensin system by deactivating Angiotensin II.30 ACE2 attaches to the outer surface 
(membrane) of cells in several organs such as the lungs, arteries, heart, kidneys, and 
intestines.31  
 
 HUMAN IMMUNE RESPONSE      Lia Yosaneri Wina Nurtias 
 
32 
 
Figure 2. ACE2 Receptors32 
 
The SARS-CoV-2 infection process begins with the attachment of Protein S to the 
ACE2 receptor, then SARS-CoV-2 enters the host cell and releases RNA.8,32 In the host cell, 
the RNA genome is translated into polyprotein (pp1a/pp1ab), then replicated (split) into small 
products by viral proteinases. The polymerase enzyme produces a series of subgenomic 
mRNAs through RNA replication which ultimately translates into relevant viral proteins. The 
new viral proteins and genomic RNA are then assembled into virions in the endoplasmic 
reticulum, and the Golgi is then transported through vesicles,8 eight released out of the cell 
and can infect other cells.8,32 The process can be observed in figure 2. 
 
 
Figure 3. How SARS-CoV-2 Infects Humans8 
 
Immune response to human 
Humans have the body's defence against various microorganisms, especially those 
that are pathogenic. This defence system has a complex and complex defence mechanism.33 
The defence system is called the immune system.34 A person's immune response to an 
antigen depends on the ability to do the right reaction to eliminate the antigen.35 This ability is 
possessed by the components of the immune system that are found in the lymphoreticular 
tissue which is located throughout the body, for example in the lymph glands; respiratory tract; 
digestive tract; and other organs.36  
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One of the body's efforts to defend itself against the entry of antigens, such as viruses, 
is to destroy the virus non-specific (innate) with the process of phagocytosis, in this case, 
leukocytes and macrophages, including phagocytic cells that play an important role.37,38 
Besides being non-specific, the process of destroying antigens is also done specifically 
(adaptive). These specific defence mechanisms produce very small groups of proteins called 
antibodies.39 These antibodies bind to specific antigens which then facilitate the destruction of 
antigens, the synthesis of these antibodies is encoded by DNA arranged together with the 
preparation of a new genome.34,40  
In the human body, there is a defence system called the immune system. The body's 
immune system functions to help repair DNA; prevent infections caused by fungi, bacteria, 
viruses, and other organisms; and produce antibodies to combat antigen attacks.34 Its job is 
to find and damage foreign organisms and their toxin products that can harm the human 
body.37 When antigens enter the human body, the body will automatically give a response 
called the immune response. Immune responses that are generally formed consist of 2 types, 
namely innate immune responses and adaptive immune responses.41  
 
 
Figure 4. Innate and Adaptive Immunity38 
 
The innate immune response becomes the first line of defence against antigens that 
enter the body, and then this response will trigger another immune response called the 
adaptive immune response.42 This adaptive immune response then helps the innate immune 
work and is tasked with remembering the antigens that infect the body to prevent future 
infections.39  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Immune Response to SARS-CoV-232 
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The immune system can work when antigens are captured by antigen-presenting 
(APC) cells, and they will swallow viruses and display viral peptides on active T-helper cells. 
T-helper cells then send signals to other immune cells, such as cytotoxic T cells and B cells. 
Cytotoxic T cells will then identify and destroy cells infected with SARS-CoV-2, whereas B 
cells will recognize SARS-CoV-2 and form antibodies against SARS-CoV-2 antigens. Long-
term memory of T cells and B cells can be in the body for a long time and can provide immunity 
when SARS-CoV-2 re-enters the host body. 
 
Innate immune response 
The innate immune response is the response carried out by the innate immune system 
that first appears when antigens begin to infect.39 The innate immune response has cellular 
and humoral systems, including cellular immune systems mediated by natural killer cells (NK), 
eosinophils, monocytes, basophils, mast cells, and phagocytes (dendritic cells; macrophages; 
neutrophils.38 NK cells are part of lymphocytes that can kill target cells directly without causing 
allergies.40 Eosinophils are part of leukocytes which make up 1-6% of total leukocytes and 
many appear in allergies.43 Monocytes are parts of leukocytes which account for 3-8% of total 
leukocytes and are classified as mononuclear phagocytes that have receptor sites on the 
membrane surface.43 Basophils are the smallest part of leukocytes (less than 2%) and play a 
role in hypersensitivity reactions that are associated mainly with IgE.43 Mast cells are cells that 
contain lots of granules that contain histamine and heparin.42  
Phagocytes consisting of dendritic cells, macrophages, and neutrophils.43 Dendritic 
cells are cells that process antigenic material and present it on the cell surface to be 
recognized by other immune cells, called antigen-presenting cells (APC), these cells serve as 
a connecting bridge between innate and adaptive immunity.44 Macrophages are the main 
mononuclear phagocyte cells in the tissue in the process of phagocytosis against foreign 
molecular complexes, monocytes that leave the blood circulation can become macrophages.45 
Neutrophils, which are part of leukocytes that make up 50-70% of the total leukocytes and 
function as a defensive line that is phagocytic and can enter the infected tissue.46  
In addition to the cellular immune system, there is also a humoral immune system that 
plays a role in the innate immune response, namely complement, mannose-binding lectin, 
antimicrobial peptides, LPS binding protein, and C-reactive protein.39 Complement is a serum 
protein that is activated by an antigen that functions as an enzyme in helping protect the body 
from infection.47 Mannose-binding lectin is a lectin that acts as a receptor connecting the virus 
with phagocytes.42 Antimicrobial peptides are peptide components in the form of amino acids 
located on the surface of epithelial cells, which help increase immunity by functioning as an 
immunomodulator.48 LPS binding protein is a serum lipid-binding glycoprotein that activates 
monocytes and macrophages to release inflammatory cytokines.49 C-reactive protein is an 
inflammatory protein found in plasma and appears in acute phase infections.50  
The innate immune response, plays an important role in response to SARS-CoV-2, the 
first response to an incoming virus is regulated mainly by alveolar macrophages, dendritic 
cells, airway epithelial cells, innate lymphocytes, and neutrophils.51 Macrophages then present 
CoV antigens to T cells.52 This process leads to activation and differentiation of T cells, 
including the production of cytokinins associated with T cell parts, followed by massive 
cytokinin release for the amplification of the immune response.52,53 Cytokines are polypeptides 
that are produced in response to antigens that mediate and regulate immunological actions 
and inflammatory reactions.53 The component of the innate immune response that arises due 
to SARS-CoV-2 infection in COVID-19 patients is presented in table 1. 
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Table 1. Default Immune Response to SARS-CoV-2 infection12,53,54,55  
No Type of innate immune The amount 
1 
Cytokines (IL-1β, IL-2, IL-6, IL-8, IL-17, G-CSF, 
GM-CSF, IP10, MCP1, MIP1α / CCL3 and TNF) 
increased 
2 Coagulation parameter (D-dimer) increased 
3 Neutrophil increased 
4 C-reactive protein increased 
5 Total lymphocytes decreased 
 
Table 1 shows that in COVID-19 patients the total lymphocytes (T lymphocytes and B 
lymphocytes) in the blood are significantly decreased, inflammatory cytokinins such as IL-6 
will also increase significantly, coagulation parameters such as D-Dimer increase abnormally, 
so CT shows expansion of lung lesions, other immune systems that are also affected by 
SARS-CoV-2 namely neutrophils and significantly increased C-reactive protein.53 Adults 
infected with SARS-CoV-2 can experience a decrease in lymphocyte counts until 
lymphocytopenia occurs, especially those who suffer from severe illness. In children with 
SARS-CoV-2, peripheral blood lymphocytes remain largely in the normal range and show 
more immune dysfunction.53  
In a report on 99 cases in Wuhan, the immune response formed by SARS-CoV-2 
infection increased total neutrophils (38%), reduced total lymphocytes (35%), increased serum 
IL-6 (52%) and increased protein c -reactive (84%).12 Most of the severe COVID-19 patients 
experienced markedly elevated serum pro-inflammatory cytokinin levels including IL-6 and IL-
1β, as well as IL-2, IL-8, IL-17, G-CSF, GM-CSF, IP10, MCP1 , MIP1α (CCL3) and TNF, which 
are characterized by cytokine storm syndrome. C-reactive protein and D-dimer are also found 
to be very high.54 Research in Wuhan, China, shows that COVID-19 damages T lymphocyte 
cells by reducing the number of T lymphocytes to lymphocytopenia in 44% of 452 patients 
with congenital diseases (hypertension, diabetes, chronic obstructive pulmonary disease). In 
this severe group, there was also an increase in the number of pro-inflammatory neutrophils 
and cytokines (TNF-α, IL-1, IL-6, and IL-8).55 High levels of pro-inflammatory cytokines can 
cause shock and damage to some tissues, such as the heart; heart; and kidney, and 
respiratory failure due to mediating extensive pulmonary pathology, which leads to infiltration 
of neutrophils and macrophages, diffuse alveolar damage with hyaline membrane formation, 
and diffuse thickening of the alveolar wall.56 In addition, splenic atrophy and lymph node 
necrosis in patients who die also results from excessive immunity.56,57  
 
Adaptive immune response 
The adaptive immune system is a development of the innate immune system. The 
adaptive immune system has the advantage of immunological memory, but it is entirely 
dependent on the innate immune system as the originator of the response. Interactions of the 
innate and adaptive immune systems that lead to the efficient introduction of antigens, but 
mal-adaptive interactions between the two can cause dangerous immunology such as 
allergies and autoimmune.43  
The adaptive immune response also has a cellular and humoral system. Cellular 
systems in adaptive immune responses include T cells38 namely cellular immunity that plays 
a role in the specific immune system consisting of CD4 + cells, CD8 + cells, naive T cells, NK 
T cells, and Th3,58 B cells38 a collection of cell populations that express various 
immunoglobulin receptors on the cell surface to recognize various antigens,59 and dendritic 
cells that act as a link between the innate immune system and the adaptive immune system.38  
As for the humoral system in the adaptive immune response that is mediated by 
antibodies (immunoglobulins secreted by B cells).38 Immunoglobulin (Ig) is a molecule found 
in plasma that can specifically respond to antigens that stimulate its production. 
Immunoglobulin is a heterotetramer molecule that contains four polypeptide chains consisting 
of two long chains called heavy chains (H), and two short chains called light chains (L).60 Data 
on adaptive immune responses that arise due to SARS-CoV-2 infection are presented in table 
2. 
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Table 2. Adaptive Immune Responses to SARS-CoV-2 Infection56,60  
No Adaptive immune type The amount 
1 Total antibody titer increased 
2 Immunoglobulin M increased 
3 Immunoglobulin G increased 
 
In COVID-19 patients, it was reported that patients with severe disease often 
experienced increased IgG responses and higher total antibody titers, which were associated 
with poorer outcomes from SARS-CoV-2 infection.57 Research conducted in China in March 
2020, showed that of 173 patients known to have a total antibody titer increased 93.1% on the 
11th day, IgM increased 82.7% on the 12th day, and IgG increased 64.7% on the day 14th, 
with 12 patients were found to have negative antibodies which may be a lack of blood samples 
at a later stage of the disease.56 Antibodies can neutralize viruses by inhibiting the attachment 
of viruses to receptors on host cells, thereby preventing intracellular penetration and 
multiplication.61 IgM and IgG antibodies in the human body are present in the serum. Serum 
COVID-19 patients who have recovered can be used for therapy of COVID-19 patients who 
have not healed because they contain antibodies.60,61 Convalescent plasma therapy in 
COVID-19 patients out of 5 patients showed viral elimination and increased antibody titer in 2 
patients, also showed improvement in lung lesions in patients on the third day after plasma 
transfusion.60  
Viruses may remain uncontrolled despite an increase in host immunity because the 
virus has mutated during the transmission process in the host body.7 RNA virus mutations 
contribute to the adaptation of viruses in creating a balance between the integrity of genetic 
information and genomic variability.20,62 The sequence of mutations is identified singly or 
double in coding 3C-Like Protease from a virus that is resistant to inhibitors. Inhibited resistant 
viruses show delays and reduce the production of infectious virus particles.63 The ability of the 
virus to defeat the immune response makes the immune response inadequate, causing viral 
replication and tissue damage. On the other hand, an excessive immune response can also 
cause autoimmune diseases.15 Autoimmune occurs when the immune system that is formed 
incorrectly identifies antigens, where cells, tissues or organs of the human body are actually 
considered as foreign objects so that they are damaged by antibodies.64  
 
4. CONCLUSION 
SARS-CoV-2 is known only to be able to infect if it finds an appropriate receptor, in this 
case, the ACE2 receptor. Viruses that have entered cells can divide RNA and damage cells, 
new viruses that form will exit the cell and infect other living cells. COVID-19 has an 
asymptomatic incubation period of 2-14 days, during which time the body will form an immune 
response. These immune responses include increasing levels of cytokines, coagulation 
parameters, C-reactive protein, neutrophils, and decreasing total lymphocytes. It is also known 
that COVID-19 patients with severe disease often experience higher total antibodies, IgM 
responses, and IgG responses than COVID-19 patients without congenital diseases. This 
review was carried out while the COVID-19 pandemic was still ongoing, so that not many 
published research data were available, it is hoped that further studies and reviews related to 
the human immune response to SARS-CoV-2 infection with more data would be obtained to 
obtain deeper and larger knowledge. 
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